GSA Capital Partners’s Corvus Pharmaceuticals CRVS Stock Holding History

GSA Capital Partners’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,188	Closed	-$109K	–	1802
2025 Q4	$109K	Sell	14,188 -387,219	-96%	-$3.05M	0.01%	1519
2025 Q3	$2.96M	Buy	401,407 +82,675	+26%	+$423K	0.25%	25
2025 Q2	$1.27M	Buy	+318,732	New	+$1.16M	0.09%	321
2025 Q1	–	Sell	-36,096	Closed	-$193K	–	1728
2024 Q4	$193K	Buy	+36,096	New	+$269K	0.01%	1422
2021 Q2	–	Sell	-95,613	Closed	-$294K	–	1354
2021 Q1	$294K	Buy	+95,613	New	+$345K	0.05%	657

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

GSA Capital Partners's CRVS Position: Q1 2026 in Review

GSA Capital Partners sold out of Corvus Pharmaceuticals (CRVS) in Q1 2026, closing a stake of 14,188 shares — an estimated $109K sold.

GSA Capital Partners first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $2.96M in Q3 2025. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

GSA Capital Partners reported no remaining Corvus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 14,188 Corvus Pharmaceuticals shares in Q1 2026, an estimated $109K.
GSA Capital Partners first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
GSA Capital Partners's Corvus Pharmaceuticals position peaked at $2.96M in Q3 2025.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.